The integration aims to build a consistent system of manufacturing everything from intermediates to API while utilizing scientific research capabilities to enhance the manufacturing technology infrastructure and make Daiichi Sankyo structurally competitive on a global level.
As part of the integration, the DSPP Odawara plant has been split off and absorbed into DSCP, which will act as the succeeding company through an Absorption-type Company Split as provided for in "The Companies Act of Japan."
The new plant, Daiichi Sankyo Chemical Pharma will spread across 133,000 m2 and manufacture API and intermediates for pharmaceuticals (olmesartan medoxomil, loxoprofen sodium, etc.)